Boston Scientific unit may pay $296m

Judge considers settlement, could offer changes

By Amy Forliti and Steve Karnowski
Associated Press / April 6, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail|
  • Print|
  • Reprints|
  • |
Text size +

ST. PAUL — Boston Scientific Corp.’s Guidant LLC division pleaded guilty yesterday to two federal misdemeanor counts alleging it failed to properly disclose changes made to some implantable heart devices.

The deal calls for Guidant to pay more than $296 million, which federal prosecutors called the largest criminal penalty ever assessed against a medical device company. The agreement does not include probation or restitution to victims.

US District Judge Donovan Frank said he will decide within three weeks whether to reject the plea deal, accept it as written, or accept it with modifications.

During yesterday’s hearing in St. Paul, Larry Knopf, vice president and secretary of Guidant, pleaded guilty on behalf of the company to two misdemeanor counts: submitting a false and misleading report to the Federal Drug Administration about one defibrillator model, and failing to notify regulators about a safety correction to another line of devices.

“Guidant’s guilty plea today is about accountability,’’ Assistant Attorney General Tony West, head of the Justice Department’s Civil Division, said in a written statement. “This successful prosecution serves as an important wake-up call to all those who seek to withhold vital information about public health and safety.’’

Attorneys for numerous patients who have sued Guidant argued against the deal because it doesn’t require the company to pay restitution to patients.

“All along Guidant was claiming they did nothing wrong,’’ said Charles Zimmerman, an attorney for victims, said in court. “Yet all along the way, your honor, they knew they were lying.’’

The 20,146 devices at issue in the criminal case are Ventak Prizm 2 and Contak Renewal 1 and 2 defibrillators, which monitor for deadly irregular heartbeats and shock the heart back to a normal rhythm.

Guidant and prosecutors reached the plea deal in principal in November, the criminal charges were filed in February, and the plea agreement was filed last month.

Prosecutors urged Frank to accept the deal despite victims’ objections. In a court filing, prosecutors argued that the specific laws under which Guidant was charged don’t call for restitution and the affected patients have other legal remedies for getting it.

The $296 million that Guidant agreed to pay includes $42 million in forfeiture funds, and the victims could petition the Justice Department for a share. Prosecutors also said most of the plaintiffs’ civil claims have been settled already and they presumably are receiving compensation.

According to the plea agreement, Guidant discovered in 2002 that its Ventak Prizm 2 DR was prone to short circuiting, which could keep it from providing lifesaving jolts. Guidant fixed the flaw that November, but in August 2003 falsely told the Food and Drug Administration the change did not affect the safety or effectiveness of the device.

Under the statute, Guidant attorney Dan Scott said, it doesn’t matter whether the company intended to mislead or the misstatement was just an error.

“Our intention is not a defense,’’ he said.

Natick-based Boston Scientific acquired Indianapolis-based Guidant for $27 billion in 2006.

The criminal case was filed in Minnesota because Guidant’s heart rhythm management unit was based in the St. Paul suburb of Arden Hills.